Evidence map›Paper›PMID 34149218›Full record

ArticleJournal of obstetrics and gynaecology of India2021

Prenatal Diagnosis by Chromosome Microarray Analysis, An Indian Experience.

Meena Bajaj Lall, Shruti Agarwal, Preeti Paliwal, Pushpa Saviour, Anju Joshi, Arti Joshi, Surbhi Mahajan, Sunita Bijarnia-Mahay, Ratna Dua Puri, I C Verma

Open access · greenAbstract read
In one paragraph

Article in Journal of obstetrics and gynaecology of India, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Meena Bajaj LallInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Shruti AgarwalInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Preeti PaliwalInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Pushpa SaviourInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Anju JoshiInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Arti JoshiInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Surbhi MahajanInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Sunita Bijarnia-MahayInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Ratna Dua PuriInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
I C VermaInstitute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, 110060 India.
Sir Ganga Ram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKaryotyping has been the gold standard for prenatal chromosome analysis. The resolution should be higher by chromosome microarray analysis (CMA). The challenge lies in recognizing benign and pathogenic or clinically significant copy number variations (pCNV) and variations of unknown significance (VOUS). The aim was to evaluate the diagnostic yield and clinical utility of CMA, to stratify the CMA results in various prenatal referral groups and to accumulate Indian data of pCNVs and VOUS for further interpretation to assist defined genetic counseling.

methodsKaryotyping and CMA were performed on consecutive referrals of 370 prenatal samples of amniotic fluid ( RESULTS AND

conclusionThe overall diagnostic yield of abnormal results was 5.40% by karyotyping and 9.18% by CMA. The highest percentage of pCNVs were found in the group with abnormal fetal ultrasound (5.40%) as compared to other groups, such as women with high maternal age (0.81%), biochemical screen positive (0.54%), previous abnormal offspring (0.81%) or heterozygous parents group (1.62%). Therefore, all women with abnormal fetal ultrasound must undergo CMA test for genotype-phenotype correlation. CMA detects known and rare deletion/duplication syndromes and characterizes marker chromosomes. Accumulation of CNV data will form an Indian Repository and also help to resolve the uncertainty of VOUS. Pretest and posttest genetic counseling is essential to convey benefits and limitations of CMA and help the patients to take informed decisions.

Indexed as

CNVMicroarrayMicrodeletionsMicroduplicationsPrenatalVOUS

Identifiers

PMID34149218
PMCPMC8167018
OpenAlexW3123186472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.